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Bifidobacteria and lactobacilli in the gut microbiome  
of children with non-alcoholic fatty liver disease:  
which strains act as health players?
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A b s t r a c t
Introduction: Non-alcoholic fatty liver disease (NAFLD), considered the lead-
ing cause of chronic liver disease in children, can often progress from non-al-
coholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH). It is clear 
that obesity is one of the main risk factors involved in NAFLD pathogenesis, 
even if specific mechanisms have yet to be elucidated. We investigated the 
distribution of intestinal bifidobacteria and lactobacilli in the stools of four 
groups of children: obese, obese with NAFL, obese with NASH, and healthy, 
age-matched controls (CTRLs). 
Material and methods: Sixty-one obese, NAFL and NASH children and 54 
CTRLs were enrolled in the study. Anthropometric and metabolic parameters 
were measured for all subjects. All children with suspected NASH underwent 
liver biopsy. Bifidobacteria and lactobacilli were analysed in children’s faecal 
samples, during a broader, 16S rRNA-based pyrosequencing analysis of the 
gut microbiome. 
Results: Three Bifidobacterium spp. (Bifidobacterium longum, Bifidobacte-
rium bifidum, and Bifidobacterium adolescentis) and five Lactobacillus spp. 
(L. zeae, L. vaginalis, L. brevis, L. ruminis, and L. mucosae) frequently recurred 
in metagenomic analyses. Lactobacillus spp. increased in NAFL, NASH, or 
obese children compared to CTRLs. Particularly, L. mucosae was significantly 
higher in obese (p = 0.02426), NAFLD (p = 0.01313) and NASH (p = 0.01079) 
than in CTRLs. In contrast, Bifidobacterium spp. were more abundant in 
CTRLs, suggesting a protective and beneficial role of these microorganisms 
against the aforementioned diseases.
Conclusions: Bifidobacteria seem to have a protective role against the devel-
opment of NAFLD and obesity, highlighting their possible use in developing 
novel, targeted and effective probiotics.
Key words: paediatric non-alcoholic fatty liver disease, gut microbiota, 
Bifidobacterium, Lactobacillus.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the 
most common cause of chronic liver disease in 
adults and children. It is regarded as a spectrum 
of hepatic conditions, which ranges from steatosis 
(non-alcoholic fatty liver – NAFL) to non-alcoholic 
steatohepatitis (NASH), with or without fibrosis 
[1]. The pathogenesis of NAFLD has been partially 
elucidated. It is generally accepted that NAFLD is 
pathogenically a  “multiple-hit” disease. This hy-
pothesis focuses on the central role of elevated 
circulating levels of free fatty acids (FFA) and insu-
lin resistance that mutually interact to cause FFA 
accumulation in hepatocytes, oxidative stress and 
an inflammatory response, providing the grounds 
for progressive liver damage [2]. Interestingly, 
several studies have shown that gut microbiota 
may also play a  key role in NAFLD development 
and progression [1]. Microbiota refers to the eco-
logical community of commensals, symbiotic and 
pathogenic microorganisms that share our body 
space and internal cavities. The human microbi-
ota consists of about 100 trillion microbial cells, 
outnumbering human cells 100 to 1 [3], with five 
phyla representing the majority of the community. 
There are approximately 160 species in the large 
intestine of any individual, and very few of these 
are shared between unrelated individuals. It has 
been demonstrated that microbiota composition 
can influence the proportion of calories absorbed 
from intestinal contents [4]. 
Indeed, bacteria play an important role in the 
absorption and emulsion of fat and fat-soluble vi-
tamins in the small bowel. The gut microbiota may 
also produce endotoxins, such as lipopolysaccha-
ride (LPS), that during impaired intestinal perme-
ability may reach the circulation, leading to extra- 
and intra-hepatic inflammatory responses, which, 
in turn, induce the progression from NAFL to NASH 
[1]. It is now recognised that the gut microbiota 
and chronic liver disease are closely linked. In ad-
dition, Ridaura et al. demonstrated a potential re-
lationship between the gut microbiome and the 
development of an obese phenotype [5]. 
Recently, our group demonstrated that om-
ics-based integrated charts of gut microbiota may 
profoundly assist in the understanding of correla-
tions between enterogradients and NAFLD onset 
and progression, thus suggesting either phylome 
or metabolome indicators that may be used as 
phenome biomarkers of gut microbiota disease [6].
Furthermore, the gut microbiota is influenced 
by diet, age, infection, hygiene habits and antibiot-
ic therapy [7]. Patients affected by NAFLD showed 
a  high prevalence of small intestine bacterial 
overgrowth (SIBO) and increased intestinal per-
meability that improved bacterial translocation, 
exposing the liver to toxic microbial metabolites 
[8, 9]. Obese patients with NAFLD displayed a re-
duction of Bacteroidetes numbers and an increase 
in Firmicutes numbers compared to patients with 
normal weight [10]. Intriguingly, the loss of weight 
in response to the limited intake of carbohydrates 
and fats increased the prevalence of Bacteroide-
tes in the intestinal microbiota [10]. Furthermore, 
studies on mice with NAFLD have demonstrated 
that lactobacilli and other probiotic bacteria re-
duced plasma cholesterol concentrations and pro-
tected against fat accumulation in adipose tissue 
and hepatocytes [8, 11].
Understanding the nature of gut dysbiosis, 
the integrity of the intestinal barrier and mecha-
nisms of the hepatic immune response to gut-de-
rived factors is potentially relevant to the devel-
opment of new therapies to treat chronic liver 
diseases [12]. The term “dysbiosis” was coined 
by Metchnikoff to describe altered pathogenic 
bacteria in the gut [13]. Dysbiosis was defined as 
qualitative and quantitative changes in the intes-
tinal flora, their metabolic activity and their local 
distribution [14]. Recently, we demonstrated [15] 
that probiotic treatment in obese children with 
NAFLD reduced their body mass index (BMI) and 
hepatic steatosis as assessed by ultrasound, and 
increased circulating levels of glucagon-like pep-
tide-1 (GLP-1), a  potent hormone released from 
intestinal L cells [16]. These encouraging results, 
also confirmed by other studies [17–19], suggest 
that improving our knowledge of bacterial species 
that live in the gut of NAFLD subjects may contrib-
ute significantly to allowing us to select the best 
probiotic(s) to strongly ameliorate liver damage. 
In a  recent, extensive characterisation of the 
gut microbiota profile of children with NAFLD com-
pared to obese and lean children without liver dis-
ease, it emerged that Oscillospira is a  marker of 
the healthy status of the liver, while Ruminococ-
cus and Dorea increased concomitantly with NAFL 
towards NASH progression [6]. However, since the 
most commercially available probiotics are Bifido-
bacterium and Lactobacillus, the aim of the present 
study was to discuss these species in terms of the 
severity of disease in order to determine which can 
be used as treatment for children with NASH.
Material and methods
This study was conducted on 61 consecutive 
overweight or obese child patients (35 males, 
aged 11.45 ±2.42 years) who were followed at the 
Hepato-Metabolic Disease Unit of Bambino Gesù 
Children’s Hospital and Research Institute (OPBG; 
Rome, Italy) in 2013. All patients were tested for 
secondary causes of fatty liver such as hepatitis, 
cytomegalovirus and Epstein-Barr viral infections, 
liver disease, autoimmune disease, metabolic liver 
disease, Wilson’s disease, coeliac disease or a de-
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ficiency of α1-antitrypsin, which were excluded 
using standard clinical, laboratory and histological 
criteria. Fifty-three patients, with BMI > 95th per-
centile, and/or hypertransaminasaemia and ste-
atosis, underwent a liver biopsy for the evaluation 
of liver damage. The study population consisted of 
three groups: 8 (13.12%) obese, 27 (44.26%) with 
NAFLD and 26 (42.62%) with definite NASH. More-
over, 54 healthy, age-matched children enrolled at 
the OPBG Human Microbiome Unit were used as 
controls (CTRLs). 
The Hospital Ethics Research Committee ap-
proved the study, which was conducted in accor-
dance with the Declaration of Helsinki (as revised 
in Seoul, Korea, October 2008). Written informed 
consent was obtained from the parents of the en-
rolled subjects. This study was approved by the 
OPBG Ethics Committee (protocol no. 768.12). 
Faecal samples were collected from all affected 
children and CTRLs, and analysed at the OPBG Hu-
man Microbiome Unit.
Anthropometric and laboratory evaluations
Anthropometric parameters, including weight, 
height, BMI, and waist circumference, were mea-
sured in all children using standardised methods. 
Obesity was defined by a  BMI ≥ 95th percentile, 
adjusted for age and sex according to World 
Health Organization growth charts. Fasting plas-
ma glucose (FPG), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), γ-glutamyl-
transferase (GGT), fasting serum triglycerides 
(TG), and total cholesterol were determined using 
standardised methods in our laboratory. Insulin 
was measured by means of a radioimmunoassay 
(MYRIA; Technogenetics, Milan, Italy). The degree 
of insulin sensitivity/resistance was determined 
by a  homeostatic model assessment (HOMA). 
A HOMA value > 2 was considered an indication 
of insulin resistance [20]. All patients underwent 
an abdominal ultrasound evaluation. Hepatic 
ultrasonography scanning by assigned and ex-
perienced radiologists, who were blinded to the 
health conditions of the patients, was performed 
on children after overnight fasting. The liver was 
graded for markers of hepatic steatosis by using 
established criteria: a bright hepatic echo pattern 
(compared with the echo response of the right 
kidney). All patient data have been previously re-
ported by Del Chierico et al. (Table I from [6]).
DNA extraction
Every stool sample collected from the 115 
children was processed for further 16S rRNA-tar-
geted metagenomic analysis. From each sample, 
DNA was extracted using the QIAamp DNA Stool 
Mini Kit (Qiagen, Germany). To start, stool sam-
ples were resuspended in 1.5 ml of phosphate- 
buffered saline, homogenised by vortexing for 
2 min and centrifuged at 20,800 × g. After the re-
moval of supernatant, the pellet was resuspend-
ed in 500 μl of phosphate-buffered saline, togeth-
er with 500 μl of beads/PBS (1 mg/μl, [w/v]; glass 
beads, acid-washed Sigma-Aldrich, St. Louis, MI, 
USA). The supernatant was collected and treated 
for one freeze-thaw cycle (–20°C/70°C) for 20 min 
each step, as previously described. After centrifu-
gation at 5200 × g for 5 min, the supernatant was 
subjected to QIAamp DNA Stool Mini Kit (Qiagen, 
Hilden, Germany) extraction according to the 
manufacturer’s instructions and then processed 
for metagenomics pipelines, as previously de-
scribed [15]. The gut microbiome was investigat-
ed by pyrosequencing V1-V3 regions of the 16S 
rRNA gene (amplicon size 520 bp) on a GS Junior 
platform (454 Life Sciences, Roche Diagnostics, 
Monza, Italy), according to the original pipelines 
described by Del Chierico et al. 2016 [6]. 
Statistical analysis
Univariate testing for differential abundanc-
es of each taxonomic unit between two or more 
groups was tested using a non-parametric Krus-
kal-Wallis H test. 
Open access data repository
Bioprojects healthy children gut microbiota: 
PRJNA268064, PRJNA 268067, PRJNA268144, 
PRJNA268157, PRJNA268286 and PRJNA280490, 
Metaomic OPBG Consortium (http://www.ncbi.
nlm.nih.gov/bioproject/?term=).
Results 
Our observation, based on the study results 
reported previously [6], highlighted the prevalent 
distribution of three main Bifidobacterium spp. 
(B. longum, B. bifidum, and B. adolescentis) and 
five Lactobacillus spp. (L. zeae, L. vaginalis, L. brevis, 
L. ruminis, and L. mucosae) that variously recurred 
in targeted metagenomic analyses. In particular, 
L. zeae was present in all four groups (i.e., obese, 
NAFL and NASH children), while L. ruminis and 
L. vaginalis were present only in the NAFL and 
NASH groups. Lactobacillus mucosae was associ-
ated with obese and NAFL groups, and L. brevis 
with NASH and CTRL groups (Figure 1). Interest-
ingly, Kruskal-Wallis H test performed among 
the groups revealed that L. mucosae was signifi-
cantly higher in obese (p = 0.02426), NAFLD (p = 
0.01313) and NASH (p = 0.01079) than in CTRLs.
In contrast, an inverse correlation between bi-
fidobacteria and NAFL and NASH was observed; 
in particular, while B. longum, B. adolescentis and 
B. bifidum were shown to be strongly reduced in 
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number in all patients, they were present in much 
higher levels in CTRLs. In fact, B. bifidum was pres-
ent only in the CTRL group, while B. adolescentis 
and B. longum were both present in high numbers 
in CTRLs, and at low levels in obese and NASH 
groups (Figure 2). 
Discussion
In recent years, scientific and pharmaceutical re-
searchers have focused their efforts on developing 
probiotic strains for the therapy of several diseases, 
since scientific evidence has shown an association 
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Figure 1. Histograms showing the percentage of relative abundances of Lactobacillus spp. distributed among the 
various groups of children. Abundances were calculated for: A – L. brevis; B – L. ruminis; C – L. zeae; D – L. vaginalis 
and E – L. mucosae
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Figure 2. Histograms showing the percentage of relative abundances of Bifidobacterium spp. distributed among the 
various groups of children. Abundances were calculated for: A – B. bifidum; B – B. longum; and C – B. adolescentis
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between a specific probiotic strain with each disor-
der [21–31]. Recently, new studies in systems biol-
ogy have substantially supported the selection of 
specific, disease-targeted probiotics [6, 32]. 
In previous studies, bifidobacteria were able 
to decrease the NAFLD activity score by reducing 
hepatic exposure to intestinal products such as 
LPS that promote hepatic inflammatory cytokine 
production and oxidative stress, leading to liver 
injury [33, 34]. Bifidobacterium longum as a pro-
biotic has been observed to reduce endotoxin lev-
els, thus promoting reduced hepatocellular injury, 
portal and parenchymal inflammation, and NASH 
activity [34]. Ren et al. highlighted the ability of bi-
fidobacteria to increase the hepatic expression of 
sirtuin 1α (SIRT1-α), which, in turn, up-regulated 
the expression of the peroxisome proliferator-ac-
tivated receptor α  (PPAR-α) and down-regulated 
the level of the sterol regulatory element-binding 
protein 1c (SREBP-1c), thus preventing the pro-
gression of NAFLD [35]. 
In the present study, we also observed an in-
crease of Lactobacillus spp. in NAFL and NASH pa-
tients compared to CTRLs. These data contrast with 
a previous experimental study demonstrating that 
the administration of a L. johnsonii-based probiotic 
to mice fed a high-fat diet (HFD) was able to pre-
vent the development of NAFLD [35]. More specif-
ically, the probiotic supplementation promoted an 
increase of lactobacilli and a decrease of bacteria 
from the Enterobacteriaceae family in the gut, pro-
viding preliminary protection. Moreover, it reduced 
both gut permeability and LPS serum levels, which 
are generally altered in mice with HFD-induced 
NAFLD. It is worth noting that dysfunctional gut per-
meability may allow liver exposure to gut-derived 
bacterial metabolites or antigens [36]. Similarly, 
gut microbiota-derived LPS leads to liver inflamma-
tion and oxidative stress [37]. Interestingly, Sohn et 
al. demonstrated that administering L. paracasei 
may prevent an increase in intestinal permeability 
in an NASH model by inhibiting the pro-inflamma-
tory M1 Kupffer cell response and promoting the 
anti-inflammatory M2 response [38]. The discrep-
ancy between these results and our study may be 
attributable to strain-specific activity of lactobacilli 
or to the use of animal models that may not be 
fully representative of human physiology. 
It is noteworthy that all obese patients en-
rolled in the present study showed a  significant 
decrease in bifidobacteria abundance compared 
to CTRLs, thus also suggesting a possible role for 
bifidobacteria in this disease. Indeed, their role in 
obesity is controversial, some studies demonstrat-
ing an involvement in body weight gain, with oth-
ers showing opposite results [39, 40]. In particular, 
B. longum has been observed to significantly re-
duce body weight gain and fat weight in a group 
of mice fed for 5 weeks with a HFD [39]. Interest-
ingly, the anti-obesity activity of probiotic micro-
organisms is often associated with a hypocholes-
terolaemic effect, through inhibition of cholesterol 
synthesis, elimination of cholesterol in faeces, 
absorption of cholesterol back into the body and 
inhibition of bile salt recycling [41, 42].
Lactobacillus spp. are associated both with nor-
mal weight and obesity; however, it is conceivable 
that these species, often found in the gut of obese 
subjects, may share with L. reuteri the same mech-
anism underlying weight gain: improvement of 
the intestine’s ability to absorb and process nutri-
ents, which increases food conversion and finally 
leads to body weight gain [43]. The hypocholes-
terolaemic properties of lactobacilli have already 
been reported. In fact, these bacteria increased 
high-density lipoprotein in serum and short-chain 
fatty acid (SCFA) concentrations in faeces, and 
promoted faecal bile acid excretion [44]. More-
over, some Lactobacillus spp. may exhibit antidia-
betic activity, with a significant reduction of blood 
glucose levels seen in infected mice [37, 45]. 
In conclusion, we highlight that bifidobacte-
ria and lactobacilli strains may differently impact 
NAFLD (Figure 3). Noticeably, we highlight that 
some Bifidobacterium spp. may have a protective 
role in the development of NASH, NAFL and obesi-
ty due to their marked reduction in patients with 
these disorders. Further studies should focus on 
assessing whether the administration of specific 
and well-selected B. adolescentis, B. longum and 
B. bifidum strains, alone or in combination with 
Oscillospira [6], may improve symptoms and the 
clinical course of NAFLD in obese children.
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